Evidence map›Paper›PMID 38506327›Full record

ArticleProteins2024

Molecular basis for differential recognition of an allosteric inhibitor by receptor tyrosine kinases.

Jyoti Verma, Harish Vashisth

Open access · hybridAbstract read
In one paragraph

Article in Proteins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Conformational dynamics in insulin receptor kinase reveal a type III allosteric pocket.Protein science : a publication of the Protein Society · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jyoti VermaDepartment of Chemical Engineering and Bioengineering, University of New Hampshire, Durham, New Hampshire, USA.
Harish VashisthDepartment of Chemical Engineering and Bioengineering, University of New Hampshire, Durham, New Hampshire, USA.ORCID 0000-0002-2087-2880
University of New Hampshire · US

Funding

Peptides and Small-molecules Targeting Signaling Proteins and Protein-Protein InterfacesR35GM138217 · NIGMS · UNIVERSITY OF NEW HAMPSHIRE · PI Harish Vashisth · 2020 to 2026
$2.9M
National Institute of Health (NIH) R35GM138217NIGMS NIH HHS R35 GM138217NSF EPSCoR OIA-1757371
6 · The paper itself

Abstract

Understanding kinase-inhibitor selectivity continues to be a major objective in kinase drug discovery. We probe the molecular basis of selectivity of an allosteric inhibitor (MSC1609119A-1) of the insulin-like growth factor-I receptor kinase (IGF1RK), which has been shown to be ineffective for the homologous insulin receptor kinase (IRK). Specifically, we investigated the structural and energetic basis of the allosteric binding of this inhibitor to each kinase by combining molecular modeling, molecular dynamics (MD) simulations, and thermodynamic calculations. We predict the inhibitor conformation in the binding pocket of IRK and highlight that the charged residues in the histidine-arginine-aspartic acid (HRD) and aspartic acid-phenylalanine-glycine (DFG) motifs and the nonpolar residues in the binding pocket govern inhibitor interactions in the allosteric pocket of each kinase. We suggest that the conformational changes in the IGF1RK residues M1054 and M1079, movement of the ⍺C-helix, and the conformational stabilization of the DFG motif favor the selectivity of the inhibitor toward IGF1RK. Our thermodynamic calculations reveal that the observed selectivity can be rationalized through differences observed in the electrostatic interaction energy of the inhibitor in each inhibitor/kinase complex and the hydrogen bonding interactions of the inhibitor with the residue V1063 in IGF1RK that are not attained with the corresponding residue V1060 in IRK. Overall, our study provides a rationale for the molecular basis of recognition of this allosteric inhibitor by IGF1RK and IRK, which is potentially useful in developing novel inhibitors with improved affinity and selectivity.

Indexed as

Molecular Dynamics SimulationProtein BindingProtein Kinase InhibitorsReceptor, IGF Type 1ThermodynamicsAllosteric RegulationAllosteric SiteBinding SitesHumansHydrogen BondingReceptor, InsulinIGF1R protein, humanProtein Kinase InhibitorsReceptor, IGF Type 1Receptor, Insulinallosteric inhibitordockinginsulin‐like growth factor receptorinsulin receptormolecular dynamics simulationreceptor tyrosine kinase

Identifiers

PMID38506327
PMCPMC11222054
OpenAlexW4393003281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.